Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.

Nat Commun · 2022 · PMC9458750 · PMID 36075914

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

This study highlighted the benefits of standard LDR and higher cell dose for robust T-cell expansion, identified product attributes associated with response, and showed a trend in tumor remodeling post T-cell infiltration.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.